ID

38945

Beskrivning

Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations; ODM derived from: https://clinicaltrials.gov/show/NCT01680328

Länk

https://clinicaltrials.gov/show/NCT01680328

Nyckelord

Versioner (1)
  1. 2019-11-14 2019-11-14 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

14 november 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Diabetes NCT01680328

Engelsk

Eligibility Diabetes NCT01680328

1 Formulär  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01680328
Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
informed consent obtained before any trial-related activities.
Beskrivning

Informed Consent

Datatyp

boolean

Alias
UMLS CUI [1]
C0021430
type 1 or type 2 diabetes
Beskrivning

Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Non-Insulin-Dependent

Datatyp

boolean

Alias
UMLS CUI [1]
C0011854
UMLS CUI [2]
C0011860
daily injection(s) with anti-diabetic drug (insulin or glucagon like peptide-1 (glp-1) analogues) via pen-injector or vial/syringe for more than 6 months
Beskrivning

Antidiabetics Injection Daily | Insulin | GLP-1 Analogue | Injection via Pen Injector | Injection via Vial | Injection via Syringe

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0935929
UMLS CUI [1,2]
C1533685
UMLS CUI [1,3]
C0332173
UMLS CUI [2]
C0021641
UMLS CUI [3]
C3273809
UMLS CUI [4,1]
C1533685
UMLS CUI [4,2]
C1550513
UMLS CUI [4,3]
C4025916
UMLS CUI [5,1]
C1533685
UMLS CUI [5,2]
C1550513
UMLS CUI [5,3]
C0184301
UMLS CUI [6,1]
C1533685
UMLS CUI [6,2]
C1550513
UMLS CUI [6,3]
C0039142
body mass index (bmi) between 18.5 and 30.0 kg/m^2 (both included)
Beskrivning

Body mass index

Datatyp

boolean

Alias
UMLS CUI [1]
C1305855
caucasians
Beskrivning

Caucasians

Datatyp

boolean

Alias
UMLS CUI [1]
C0043157
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
known or suspected hypersensitivity to needle, ink ball pen or other that are in contact with the injection area during the clinical visit
Beskrivning

Hypersensitivity Needle | Other Coding

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0027551
UMLS CUI [2]
C3846158
previous participation in this trial. participation is defined as: screened
Beskrivning

Study Subject Participation Status

Datatyp

boolean

Alias
UMLS CUI [1]
C2348568
receipt of any investigational medicinal product that can influence pain perception within 14 days before screening
Beskrivning

Investigational New Drugs Influence Pain Perception

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C4054723
UMLS CUI [1,3]
C3714605
injection of more than 40 units of insulin per injection
Beskrivning

Injection Insulin Unit Quantity

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1533685
UMLS CUI [1,2]
C0021641
UMLS CUI [1,3]
C0869039
UMLS CUI [1,4]
C1265611
continuous subcutaneous insulin infusion use within the last 6 months
Beskrivning

Continuous subcutaneous infusion of insulin

Datatyp

boolean

Alias
UMLS CUI [1]
C0393124
continuous glucose monitoring use within the last 6 months
Beskrivning

Continuous glucose monitoring

Datatyp

boolean

Alias
UMLS CUI [1]
C4523945
intake of any pain-relieving or analgesic within the last week (excluding low dose aspirin in cardio vascular prophylactic doses)
Beskrivning

Administration of analgesic | Exception Aspirin Low Dose

Datatyp

boolean

Alias
UMLS CUI [1]
C0262176
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C2608320
known active or in-active skin disease in the injection area or that may affect pain perception
Beskrivning

Dermatologic disorder Injection Area | Dermatologic disorder Affecting Pain Perception

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0037274
UMLS CUI [1,2]
C1533685
UMLS CUI [1,3]
C0205146
UMLS CUI [2,1]
C0037274
UMLS CUI [2,2]
C0392760
UMLS CUI [2,3]
C3714605
anti-coagulant treatment within the last month (low dose of aspirin in cardiovascular prophylactic doses is allowed. however, not on the day of the injections)
Beskrivning

Anticoagulant therapy

Datatyp

boolean

Alias
UMLS CUI [1]
C0150457
Tillbaka till toppen

Similar models

Eligibility Diabetes NCT01680328

1 Formulär
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01680328
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
informed consent obtained before any trial-related activities.
boolean
C0021430 (UMLS CUI [1])
Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus, Non-Insulin-Dependent
Item
type 1 or type 2 diabetes
boolean
C0011854 (UMLS CUI [1])
C0011860 (UMLS CUI [2])
Antidiabetics Injection Daily | Insulin | GLP-1 Analogue | Injection via Pen Injector | Injection via Vial | Injection via Syringe
Item
daily injection(s) with anti-diabetic drug (insulin or glucagon like peptide-1 (glp-1) analogues) via pen-injector or vial/syringe for more than 6 months
boolean
C0935929 (UMLS CUI [1,1])
C1533685 (UMLS CUI [1,2])
C0332173 (UMLS CUI [1,3])
C0021641 (UMLS CUI [2])
C3273809 (UMLS CUI [3])
C1533685 (UMLS CUI [4,1])
C1550513 (UMLS CUI [4,2])
C4025916 (UMLS CUI [4,3])
C1533685 (UMLS CUI [5,1])
C1550513 (UMLS CUI [5,2])
C0184301 (UMLS CUI [5,3])
C1533685 (UMLS CUI [6,1])
C1550513 (UMLS CUI [6,2])
C0039142 (UMLS CUI [6,3])
Body mass index
Item
body mass index (bmi) between 18.5 and 30.0 kg/m^2 (both included)
boolean
C1305855 (UMLS CUI [1])
Caucasians
Item
caucasians
boolean
C0043157 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Needle | Other Coding
Item
known or suspected hypersensitivity to needle, ink ball pen or other that are in contact with the injection area during the clinical visit
boolean
C0020517 (UMLS CUI [1,1])
C0027551 (UMLS CUI [1,2])
C3846158 (UMLS CUI [2])
Study Subject Participation Status
Item
previous participation in this trial. participation is defined as: screened
boolean
C2348568 (UMLS CUI [1])
Investigational New Drugs Influence Pain Perception
Item
receipt of any investigational medicinal product that can influence pain perception within 14 days before screening
boolean
C0013230 (UMLS CUI [1,1])
C4054723 (UMLS CUI [1,2])
C3714605 (UMLS CUI [1,3])
Injection Insulin Unit Quantity
Item
injection of more than 40 units of insulin per injection
boolean
C1533685 (UMLS CUI [1,1])
C0021641 (UMLS CUI [1,2])
C0869039 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,4])
Continuous subcutaneous infusion of insulin
Item
continuous subcutaneous insulin infusion use within the last 6 months
boolean
C0393124 (UMLS CUI [1])
Continuous glucose monitoring
Item
continuous glucose monitoring use within the last 6 months
boolean
C4523945 (UMLS CUI [1])
Administration of analgesic | Exception Aspirin Low Dose
Item
intake of any pain-relieving or analgesic within the last week (excluding low dose aspirin in cardio vascular prophylactic doses)
boolean
C0262176 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C2608320 (UMLS CUI [2,2])
Dermatologic disorder Injection Area | Dermatologic disorder Affecting Pain Perception
Item
known active or in-active skin disease in the injection area or that may affect pain perception
boolean
C0037274 (UMLS CUI [1,1])
C1533685 (UMLS CUI [1,2])
C0205146 (UMLS CUI [1,3])
C0037274 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C3714605 (UMLS CUI [2,3])
Anticoagulant therapy
Item
anti-coagulant treatment within the last month (low dose of aspirin in cardiovascular prophylactic doses is allowed. however, not on the day of the injections)
boolean
C0150457 (UMLS CUI [1])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial